A prior briefing dated 2026-07-23 covered ISRG's Q2 2026 period, noting that broader market conditions during the quarter included geopolitical turbulence stemming from the US-Iran military conflict. A separate briefing from 2026-07-17 detailed that US forces completed a sixth consecutive night of strikes on Iranian targets, with Brent crude rising to $85.06 per barrel, up approximately 1% on the session. These cross-asset developments created volatility across equity markets, including in the healthcare and medical device segments where ISRG operates [Brief - 2026-07-17] [Brief - 2026-07-23].
For the trailing twelve months ending 2026-06-30, Intuitive Surgical recorded revenue of $11.03 billion, representing year-over-year growth of 18.5%. Net income over the same period was $3.14 billion, with a net margin of 28.4% and a gross margin of 66.7%. Operating margin stood at 31.3%. EPS grew 26.5% year-over-year. The company carried $2.76 billion in cash with zero total debt reported. The market capitalisation was approximately $142.0 billion, and the price-to-earnings ratio was 46.07 [SEC 10-Q - ISRG - 2026-06-30].
Insider activity is the primary trigger for this report. In August 2026, nine insider transactions were recorded for ISRG, with a net directional bias toward selling and a net disposal value of approximately $4.38 million. No institutional 13F data was provided for this reporting period, so no holdings changes from named filers are cited here [SEC Form 4 - ISRG - 2026-08].
The prevailing macroeconomic rate environment as of the generation date shows the 10-year US Treasury yield (DGS10) at 4.70% and the 2-year yield (DGS2) at 4.22%, producing a normal yield curve with a spread of 48 basis points. This rate configuration forms part of the broader financial backdrop against which ISRG's valuation multiples and capital structure are contextualised [FRED DGS10] [FRED DGS2].